Drug Trial Radar · NCT00637377
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)
Last checked: Nov 20, 2026Latest source record: Dec 12, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,240
Actual
Start
Apr 2008
Primary completion
Sep 2010
Study completion Aug 2011
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Mar 18, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a phase III, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration. Approximately 1200 patients will be randomized in Europe, Asia, Japan, Australia and South America.
Conditions
- Macular Degeneration
Interventions
RanibizumabDrug
Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)Biological
Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)Biological
Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)Biological
Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF)Time frame: At week 52
Locations
189 sites in 26 countries. Site status is shown where the registry gives one.
Site not named
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Site not named
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Site not named
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Site not named
Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
Site not named
Córdoba, Córdoba Province, Argentina
Site not named
Rosario, Santa Fe Province, Argentina
Site not named
Parramatta, Australia
Site not named
Chatswood, New South Wales, Australia
Site not named
Sydney, New South Wales, Australia
Site not named
Westmead, New South Wales, Australia
Site not named
East Melbourne, Victoria, Australia
Site not named
Parkville, Victoria, Australia
Site not named
Nedlands, Western Australia, Australia
Site not named
Innsbruck, Austria
Site not named
Linz, Austria
Site not named
Vienna, Austria
Site not named
Liège, Belgium
Site not named
Minas Gerais, Brazil
Site not named
Ribeirão Preto, São Paulo, Brazil
Site not named
São Paulo, São Paulo, Brazil
Site not named
São Paulo, São Paulo, Brazil
Site not named
Medellín, Antioquia, Colombia
Site not named
Bogotá, Bogota D.C., Colombia
Site not named
Cali, Cauca Department, Colombia
Site not named
Brno, Czechia
Site not named
Olomouc, Czechia
Site not named
Prague, Czechia
Site not named
Prague, Czechia
Site not named
Ústí nad Labem, Czechia
Site not named
Besançon, France
Site not named
Bordeaux, France
Site not named
Dijon, France
Site not named
Lyon, France
Site not named
Lyon, France
Site not named
Marseille, France
Site not named
Paris, France
Site not named
Paris, France
Site not named
Nantes, Cedex 1, France
Site not named
Paris, Cedex 12, France
Site not named
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Showing 40 of 189 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.